

Pancreatic Cancer Committee meeting 7

Date: 13/12/2016

Location: RCOG, London

Minutes: Draft

Committee members present:		
John Primrose (Chair)		(Present for notes 1 – 5)
John Neoptolemos (Clinical Lead)		(Present for notes 1 – 5)
Fiona Campbell		(Present for notes 1 – 5)
Margred Capel		(Present for notes 1 – 5)
Richard Charnley		(Present for notes 1 – 5)
Pippa Corrie		(Present for notes 1 – 5)
Lesley Goodburn		(Present for notes 1 – 5)
Philip Whelan		(Present for notes 1 – 5)
Derek O'Reilly		(Present for notes 1 – 5)
Somnath Mukherjee		(Present for notes 1 – 5)
Kofi Oppong		(Present for notes 1 – 5)
Anna Jewell		(Present for notes 4 – 5)
Dawn Elliot		(Present for notes 1 – 5)
Mark Callaway		(Present for notes 1 – 5)

In attendance:		
Angela Bennett	NGA Guideline Lead	(Present for notes 1 – 5)
John Graham	NGA Clinical Advisor	(Present for notes 1 – 5)
James Hawkins	NGA Health Economist	(Present for notes 1 – 5)
Ferruccio Pelone	NGA Assistant Reviewer	(Present for notes 1 – 5)
Fionnuala O'Brien	NGA Project Manager	(Present for notes 1 – 5)
Linyun Fou	NGA Systematic Reviewer	(Present for notes 1 – 5)

Observers:	
None	

Apologies:	
Laura McGeeney	Committee member

Suzanne Joharchi	Committee member
Katie Perryman Ford	NICE Guideline Commissioning Manager

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 7th meeting on Pancreatic Cancer.

No members of the public asked to observe the meeting.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: the draft results of a network meta-analysis for topic 5D, and reviewing the clinical and economic evidence for topic 5F

2. Declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was pancreatic cancer.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Received an honorarium from Mylan for speaking at training event on pancreatitis, November Manchester	Financial personal, non-specific	Declare and participate
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal	Received travel, accommodation and honorarium from Mylan for speaking on NCEPOD report on acute pancreatitis, November 2016, Belfast	Financial personal, non-specific	Declare and participate

	Infirmery, Central Manchester NHS Foundation Trust			
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmery, Central Manchester NHS Foundation Trust	Attended a meeting on HPB cancer in November 2016 which was sponsored by Myla and Angiodynamics (no role in agenda). Sponsorship was for the venue for the meeting no money received personally.	Non- personal financial, specific	Declare and participate (expenses within NICE expenses and hospitality policy)
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmery, Central Manchester NHS Foundation Trust	Received travel and accommodation expenses and an honorarium from the Central European Cooperative Oncology Group (CECOG) to attend a conference on pancreatic cancer in November 2016.	Personal financial, non- specific	Declare and participate - expenses within NICE expenses and hospitality policy and CECOG does not manufacture any products (its interests are education and clinical trials)
Philip Whelan	Macmillan Clinical Nurse Specialist, Royal Liverpool University Hospital	Presented on the role of Cancer Nurse Specialists in pancreatic cancer and UK services at the Central European Cooperative Oncology Group (CECOG), Pancreas Academy in November 2016. Received reimbursement of travel and accommodation (no fee received)	Personal financial, non- specific	Declare and participate (expenses within NICE expenses and hospitality policy)

Anna Jewell	Lay member	Presented on the role of information for pancreatic cancer patients at the Central European Cooperative Oncology Group (CECOG), Pancreas Academy in November 2016. Received reimbursement of travel and accommodation and an honorarium payment for speaking which went to Pancreatic Cancer UK	Personal financial, non-specific	Declare and participate - expenses within NICE expenses and hospitality policy and CECOG does not manufacture any products (its interests are education and clinical trials and honorarium not personally received)
John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Joint PI on a trial investigating the prospective validation of IMMray™ PanCan-d (a new diagnostic method in pancreatic cancer) in Europe. Sponsored by Immunovia	Non-personal financial, non-specific	Declare and participate as this intervention is not being investigated by the guideline
John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Provided consultancy for RedxOncology on the development of porcupine inhibitor, RXC004, in patients with pancreatic cancer harbouring RNF43 LoF mutations. No fee paid at this time.	Personal non-financial, non-specific	Declare and participate as RXC004 is not being investigated by the guideline
John Neoptolemos	The Owen and Ellen	Provided consultancy on 28/10/2016 to Sun	Personal financial,	Declare and withdraw

	Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Biopharma on SBP-101 (a polyamine inhibitor for pancreatic cancer). Will be paid a fee for advice	specific	from any topics that include SBP-101 as an intervention (no topics are looking at this intervention)
Lesley Goodburn	Lay member	Started a new position as NHS England as a Patient Experience manager	Personal financial, non-specific	Declare and participate.
Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Attended ESMO Oncology Conference Denmark 2016. Celgene paid for accommodation, flights and registration. General oncology conference.	Personal financial, non-specific	Declare and participate (expenses are within the NICE Hospitality policy)

The Chair and a senior member of the Developer’s team noted that the interests declared did not prevent the other attendees from fully participating in the meeting.

The Chair and a senior member of the Developer’s team noted that John Neoptolemos would need to withdraw from discussion of topic 5F due to a conflict of interest with GV1001. The Committee agreed that they would not be making any recommendations relating to GV1001 (based on the evidence) or discussing it any further. Chair Person’s action that John Neoptolemos be allowed to participate in discussion of recommendations for topic 5F as the intervention to which the conflict related would not be discussed or included in the recommendations.

3. Minutes of last meeting

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

4. Presentations

The Chair introduced James Hawkins, Health Economist, who gave a presentation about the network meta-analysis being conducted for question 5d of the guideline. James then took questions from the group.

The Chair introduced Linyun Fou, Systematic Reviewer, who gave a presentation on the clinical evidence for question 5F. Lin then took questions from the group. The Committee then discussed the issues presented in relation to this guideline.

The Chair introduced James Hawkins, Health Economist, who gave a presentation on the economic evidence for question 5F. James then took questions from the group. The Committee then discussed the issues presented in relation to this guideline.

5. Questions and discussion

The Committee discussed the clinical and economic evidence presented for questions 5F and drafted recommendations and the section of the guideline linking evidence to recommendations.

6. Any other business

No service user or carer concerns were raised.

Date of next meeting: 08/02/2017

Location of next meeting: RCOG, London